Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 5, 2011, Pages 541-562

  Mao, Zhongping ^a,e   Wheeler, Jeff J ^b   Townsend, Robert ^a   Gao, Yuying ^c   Kshirsagar, Smita ^d   Keirns, James J ^a  

^a Astellas Pharma Global Development US Inc   (United States)

^b Cardiome Pharma Corp   (Canada)

^c Quantitative Solutions   (United States)

^d PHARSIGHT CORPORATION   (United States)

^e Impax Laboratories Inc   (United States)

Author keywords

Atrial fibrillation; Atrial flutter; Sinus rhythm; Vernakalant

Indexed keywords

ANTIARRHYTHMIC AGENT; DIGOXIN; PLACEBO; VERNAKALANT;

ARTICLE; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG RESPONSE; DRUG SAFETY; FRIDERICIA FORMULA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART RATE; HUMAN; HYPOTENSION; MATHEMATICAL PARAMETERS; MEDIAN EFFECTIVE CONCENTRATION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BLOOD PRESSURE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; HYPOTENSION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PYRROLIDINES;

EID: 80053204194     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9207-3     Document Type: Article

References (26)

1. AS Go EM Hylek KA Phillips Y Chang LE Henault JV Selby DE Singer 2001 Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2370 2375 11343485 10.1001/jama.285.18.2370 1:STN:280:DC%2BD3M3ntleitQ%3D%3D (Pubitemid 32424106)
2. WB Kannel PA Wolf EJ Benjamin D Levy 1998 Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates Am J Cardiol 82 2N 9N 9809895 10.1016/S0002-9149(98)00583-9 1:STN:280:DyaK1M%2FisFOltQ%3D%3D (Pubitemid 28507114)
3. DM Lloyd-Jones TJ Wang EP Leip MG Larson D Levy RS Vasan RB D'Agostino JM Massaro A Beiser PA Wolf EJ Benjamin 2004 Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 1042 1046 15313941 10.1161/01.CIR.0000140263.20897.42 (Pubitemid 39319000)
4. Ayala C, Wattigney W, Croft J, Hyduk A, Mensah G (2003) Public health and aging: atrial fibrillation as a contributing cause of death and medicare hospitalization. 1999 February 20. http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5207a2.htm. Accessed 14 Dec 2010
5. G Boysen J Nyboe M Appleyard PS Sorensen J Boas F Somnier G Jensen P Schnohr 1988 Stroke incidence and risk factors for stroke in Copenhagen, Denmark Stroke 19 1345 1353 3188119 10.1161/01.STR.19.11.1345 1:STN:280: DyaL1M%2FksV2quw%3D%3D
6. MW Knuiman HT Vu 1996 Risk factors for stroke mortality in men and women: The Busselton Study J Cardiovasc Risk 3 447 452 9048260 10.1097/00043798- 199610000-00006 1:STN:280:DyaK2s3gtVehtw%3D%3D (Pubitemid 27051343)
7. PA Wolf RD Abbott WB Kannel 1991 Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 983 988 1866765 10.1161/01.STR.22.8.983 1:STN:280:DyaK3Mzislektg%3D%3D
8. EJ Benjamin PA Wolf RB D'Agostino H Silbershatz WB Kannel D Levy 1998 Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 946 952 9737513 1:STN:280:DyaK1cvgslGgsw%3D%3D (Pubitemid 28446646)
9. AV Raghavan WW Decker TD Meloy 2005 Management of atrial fibrillation in the emergency department Emerg Med Clin N Am 23 1127 1139 10.1016/j.emc.2005.07. 013 (Pubitemid 41403274)
10. A Wakai JO O'Neill 2003 Emergency management of atrial fibrillation Postgrad Med J 79 313 319 12840118 10.1136/pmj.79.932.313 1:STN:280: DC%2BD3szht1SgsQ%3D%3D (Pubitemid 36826649)
11. D Roy BH Rowe IG Stiell B Coutu JH Ip D Phaneuf J Lee H Vidaillet G Dickinson S Grant AM Ezrin GN Beatch 2004 A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J Am Coll Cardiol 44 2355 2361 15607398 10.1016/j.jacc.2004.09.021 1:CAS:528:DC%2BD2cXhtVyqs7%2FM (Pubitemid 39647610)
12. G Nichol F McAlister B Pham A Laupacis B Shea M Green A Tang G Wells 2002 Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Heart 87 535 543 12010934 10.1136/heart.87.6.535 1:CAS:528:DC%2BD38XmslOgtbY%3D (Pubitemid 34547976)
13. D Fedida PM Orth JY Chen S Lin B Plouvier G Jung AM Ezrin GN Beatch 2005 The mechanism of atrial antiarrhythmic action of RSD1235 J Cardiovasc Electrophysiol 16 1227 1238 16302909 10.1111/j.1540-8167.2005.50028.x
14. PM Orth JC Hesketh CK Mak Y Yang S Lin GN Beatch AM Ezrin D Fedida 2006 RSD1235 blocks late INa and suppresses early after depolarizations and torsades de pointes induced by class III agents Cardiovasc Res 70 486 496 16545351 10.1016/j.cardiores.2006.01.026 1:CAS:528:DC%2BD28Xks1Wlurk%3D
15. D Roy CM Pratt C Torp-Pedersen DG Wyse E Toft S Juul-Moller T Nielsen SL Rasmussen IG Stiell B Coutu JH Ip EL Pritchett AJ Camm 2008 Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial Circulation 117 1518 1525 18332267 10.1161/CIRCULATIONAHA.107.723866 1:CAS:528:DC%2BD1cXjtlWnsb4%3D (Pubitemid 351440640)
16. Mao ZL, Townsend RW, Gao CY, Wheeler JJ, Kastrissios H, Keirns J (2011) Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter. J Clin Pharmacol [Epub ahead of print]
17. ZL Mao A Alak JJ Wheeler J Keirns 2011 Disposition and mass balance of 14C-vernakalant after single intravenous and oral doses in healthy volunteers Drug Met Lett 5 2 114 125 10.2174/187231211795305249 1:CAS:528: DC%2BC3MXltF2mt7s%3D
18. Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Camm J (in preparation) Efficacy and safety of vernakalant hydrochloride injection in the treatment of atrial flutter: a randomized, controlled trial (scene 2) (in preparation)
19. PR Kowey P Dorian LB Mitchell CM Pratt D Roy PJ Schwartz J Sadowski D Sobczyk A Bochenek E Toft 2009 Vernakalant hydrochloride for the rapid conversion of atrial fibrillation following cardiac surgery: a randomized, double-blind, placebo-controlled trial Circ Arrhythm Electrophysiol 2 652 659 19948506 10.1161/CIRCEP.109.870204
20. CM Pratt D Roy C Torp-Pedersen DG Wyse E Toft S Juul-Moller E Retyk DH Drenning 2010 Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation Am J Cardiol 106 1277 1283 21029824 10.1016/j.amjcard.2010.06.054 1:CAS:528:DC%2BC3cXhtlKjur%2FL
21. IG Stiell JS Roos KM Kavanagh G Dickinson 2010 A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm Am Heart J 159 1095 1101 20569725 10.1016/j.ahj.2010.02.035 1:CAS:528: DC%2BC3cXntVSltLk%3D
22. ZL Mao JJ Wheeler L Clohs GN Beatch J Keirns 2009 Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors J Clin Pharmacol 49 17 29 18927241 1:CAS:528:DC%2BD1MXhslSrsbs%3D
23. RM Savic MO Karlsson 2009 Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions AAPS J 11 558 569 19649712 10.1208/s12248-009-9133-0
24. G Yi XH Guo M Reardon MM Gallagher K Hnatkova AJ Camm M Malik 1998 Circadian variation of the QT interval in patients with sudden cardiac death after myocardial infarction Am J Cardiol 81 950 956 9576152 10.1016/S0002- 9149(98)00071-X 1:STN:280:DyaK1c3jsFKrtw%3D%3D (Pubitemid 28183658)
25. VK Yeragani R Pohl R Balon VC Jampala A Jayaraman 2002 Twenty-four-hour QT interval variability: increased QT variability during sleep in patients with panic disorder Neuropsychobiology 46 1 6 12207139 10.1159/000063568 (Pubitemid 35002310)
26. L Bertilsson 1995 Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19 Clin Pharmacokinet 29 192 209 8521680 10.2165/00003088-199529030-00005 1:CAS:528:DyaK2MXotVOksLo%3D